activities < activity < actor

Facettes : Author.f AffPays.f AffOrg.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 162.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000009 (2008)	Misato Hashizume [Japon] ; Masahiko Mihara [Japon]	Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling
000011 (2012)	Emilio Besada [Norvège] ; Johannes C. Nossent [Norvège]	Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab
000013 (2013)	Micha Levi [États-Unis] ; Susan Grange [États-Unis] ; Nicolas Frey [Suisse]	Exposure‐Exposure Relationship of Tocilizumab, an Anti–IL‐6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis
000015 (2013)	Jörg Kaufmann [Allemagne] ; Eugen Feist [Allemagne] ; Anne-Eve Roske [Allemagne] ; Wolfgang A. Schmidt [Allemagne]	Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice
000016 (2009)	Mao Mao An [République populaire de Chine] ; Zui Zou [République populaire de Chine] ; Hui Shen [République populaire de Chine] ; Jun Dong Zhang [République populaire de Chine] ; Yong Bing Cao [République populaire de Chine] ; Yuan Ying Jiang [République populaire de Chine]	The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials
000036 (2013)	Ruchika Goel [Inde] ; Debashish Danda [Inde] ; Sathish Kumar [Inde] ; George Joseph [Inde]	Rapid control of disease activity by tocilizumab in 10 ‘difficult‐to‐treat’ cases of Takayasu arteritis
000048 (2012)	Hiroki Wakabayashi [Japon] ; Masahiro Hasegawa [Japon] ; Yosuke Nishioka [Japon] ; Yukari Minami [Japon] ; Kusuki Nishioka [Japon] ; Akihiro Sudo [Japon]	Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure
000050 (2011)	Masaaki Hiura [Japon] ; Shintaro Abe ; Akinari Tabaru ; Shohei Shimajiri ; Kentaro Hanami [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] ; Masaru Harada	Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis
000083 (2012)	Yasuhiko Hirabayashi [Japon] ; Tomonori Ishii [Japon]	The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab
000085 (2011)	Hiroki Wakabayashi [Japon] ; Akihiro Sudo [Japon] ; Yosuke Nishioka [Japon] ; Masahiro Hasegawa [Japon] ; Yukari Minami [Japon] ; Kusuki Nishioka [Japon]	Repeat etanercept administration restores clinical response of patients with rheumatoid arthritis
000091 (2012)	Sooha Kim [Royaume-Uni] ; Andrew J. K. Östör [Royaume-Uni] ; Muhammad K. Nisar [Royaume-Uni]	Interleukin-6 and cytochrome-P450, reason for concern?
000092 (2009)	Yasuhiko Hirabayashi [Japon] ; Tomonori Ishii [Japon] ; Hideo Harigae [Japon]	Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice
000094 (2011)	Maasa Hama [Japon] ; Takeaki Uehara [Japon] ; Kaoru Takase [Japon] ; Atsushi Ihata [Japon] ; Atsuhisa Ueda [Japon] ; Mitsuhiro Takeno [Japon] ; Kazuya Shizukuishi [Japon] ; Ukihide Tateishi [Japon] ; Yoshiaki Ishigatsubo [Japon]	Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab—preliminary data
000098 (2012)	H.-I. Huppertz [Allemagne]	Biologika bei Kindern und Jugendlichen zur Behandlung rheumatischer Erkrankungen
000117 (2010)	C. B. Confavreux [France] ; R. D. Chapurlat [France]	Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis
000133 (2009)	Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami [Japon] ; Satoshi Yamasaki [Japon] ; Takahiro Imazato [Japon] ; Naoki Iwamoto [Japon] ; Keita Fujikawa [Japon] ; Toshiyuki Aramaki [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Hiroaki Ida [Japon] ; Tomoki Origuchi [Japon] ; Yukitaka Ueki [Japon] ; Katsumi Eguchi [Japon]	Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
000135 (2012)	K. Krüger [Allemagne] ; J. Wollenhaupt [Allemagne] ; K. Albrecht [Allemagne] ; R. Alten [Allemagne] ; M. Backhaus [Allemagne] ; C. Baerwald [Allemagne] ; W. Bolten [Allemagne] ; J. Braun [Allemagne] ; H. Burkhardt [Allemagne] ; G. Burmester [Allemagne] ; M. Gaubitz [Allemagne] ; A. Gause [Allemagne] ; E. Gromnica-Ihle [Allemagne] ; H. Kellner [Allemagne] ; J. Kuipers [Allemagne] ; A. Krause [Allemagne] ; H.-M. Lorenz [Allemagne] ; B. Manger [Allemagne] ; H. Nü Lein [Allemagne] ; H.-G. Pott [Allemagne] ; A. Rubbert-Roth [Allemagne] ; M. Schneider [Allemagne] ; C. Specker [Allemagne] ; H. Schulze-Koops [Allemagne] ; H.-P. Tony [Allemagne] ; S. Wassenberg [Allemagne] ; U. Müller-Ladner [Allemagne]	S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis 2012
000143 (2012)	Maxime Samson [France] ; Sylvain Audia [France] ; Nona Janikashvili [France] ; Marion Ciudad [France] ; Malika Trad [France] ; Jennifer Fraszczak [France] ; Paul Ornetti [France] ; Jean-Francis Maillefert [France] ; Pierre Miossec [France] ; Bernard Bonnotte [France]	Brief Report: Inhibition of interleukin‐6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis
000147 (2010)	Tamotsu Kamishima [Japon] ; Kazuhide Tanimura [Japon] ; Masato Shimizu [Japon] ; Megumi Matsuhashi [Japon] ; Jun Fukae [Japon] ; Yujiro Kon [Royaume-Uni] ; Hiromi Hagiwara [Japon] ; Akihiro Narita [Japon] ; Yuko Aoki [Japon] ; Naoki Kosaka [Japon] ; Tatsuya Atsumi [Japon] ; Hiroki Shirato [Japon] ; Satoshi Terae [Japon]	Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger
000150 (2012)	O. Psenak [Autriche] ; A. Studnicka-Benke [Autriche] ; R. Greil [Autriche]	Sicherheit der Immunsuppressiva
000154 (2011)	Atsushi Kaneko [Japon] ; Daihei Kida [Japon] ; Kiwamu Saito [Japon] ; Masami Tsukamoto [Japon] ; Tomotaro Sato [Japon]	Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "activity" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "activity" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    activity
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021